新型SALT-M评分预测重度慢加急性肝衰竭患者移植后1年死亡率
本研究在美国15个肝移植中心回顾性纳入2014-2019年接受肝移植的重度慢加急性肝衰竭患者,开发并外部验证了预测移植后1年死亡率的SALT-M评分及移植后中位住院时间评分。SALT-M评分在推导队列c-statistic为0.72,在法国验证队列为0.80;年龄、呼吸衰竭、BMI和感染可独立预测中位住院时间。
要点
- SALT-M评分用于预测重度慢加急性肝衰竭患者肝移植后1年死亡率。
- 推导队列c-statistic为0.72,外部验证队列为0.80。
- 年龄、呼吸衰竭、BMI和感染可独立预测移植后中位住院时间。
核心结论
- SALT-M评分可预测慢加急性肝衰竭患者肝移植后1年内死亡率,ACLF-LT-LoS评分可预测移植后中位住院时间;未来使用这些评分可能有助于确定移植获益。
研究设计与样本
- 在美国15个肝移植中心回顾性识别2014-2019年接受肝移植的重度慢加急性肝衰竭患者队列,随访至2022年1月,最终模型预测因素基于临床标准选择,并在两个法国队列中进行外部验证。
- 共纳入735例患者,其中521例(70.8%)为重度慢加急性肝衰竭,包括120例ACLF-3患者(外部队列)。
主要发现
- 重度慢加急性肝衰竭患者中位年龄55岁,104例(19.9%)在肝移植后1年内死亡。
- 最终模型包含年龄>50岁、使用1种或≥2种正性肌力药、存在呼吸衰竭、糖尿病和BMI(连续变量)。
- c-statistic在推导队列为0.72,在验证队列为0.80,基于观察/预期概率图显示区分度和校准度充分。
- 年龄、呼吸衰竭、BMI和感染可独立预测中位住院时间。
关键数值与推荐
- SALT-M评分预测肝移植后1年死亡率,推导队列c-statistic为0.72,外部验证队列为0.80。
- ACLF-LT-LoS评分预测肝移植后中位住院时间。
临床怎么用
- 作者认为这些模型可用于讨论重度慢加急性肝衰竭患者肝移植的风险/获益。
- 作者指出该评分远非完美,使用时需考虑患者偏好和中心特异性因素等其他因素。
局限性
- 作者指出该评分远非完美,使用时需考虑患者偏好和中心特异性因素等其他因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Twenty-eight-day mortality ranges from 30-90% in patients with acute-on-chronic liver failure grades 2/3 (severe ACLF). Though liver transplantation (LT) has demonstrated a survival benefit, the scarcity of donor organs and uncertainty regarding post-LT mortality among patients with severe ACLF may cause hesitancy. We developed and externally validated a model to predict 1-year post-LT mortality in severe ACLF, called the Sundaram ACLF-LT-Mortality (SALT-M) score, and estimated the median length of stay (LoS) after LT (ACLF-LT-LoS). METHODS: In 15 LT centers in the US, we retrospectively identified a cohort of patients with severe ACLF transplanted between 2014-2019, followed up to Jan'2022. Candidate predictors included demographics, clinical and laboratory values, and organ failures. We selected predictors in the final model using clinical criteria and externally validated them in two French cohorts. We provided measures of overall performance, discrimination, and calibration. We used multivariable median regression to estimate LoS after adjusting for clinically relevant factors. RESULTS: We included 735 patients, of whom 521 (70.8%) had severe ACLF (120 ACLF-3, external cohort). The median age was 55 years, and 104 with severe ACLF (19.9%) died within 1-year post-LT. Our final model included age >50 years, use of 1/≥2 inotropes, presence of respiratory failure, diabetes mellitus, and BMI (continuous). The c-statistic was 0.72 (derivation) and 0.80 (validation), indicating adequate discrimination and calibration based on the observed/expected probability plots. Age, respiratory failure, BMI, and presence of infection independently predicted median LoS. CONCLUSIONS: The SALT-M score predicts mortality within 1-year after LT in patients with ACLF. The ACLF-LT-LoS score predicted median post-LT stay. Future studies using these scores could assist in determining transplant benefits. IMPACT AND IMPLICATIONS: Liver transplantation (LT) may be the only life-saving procedure available to patients with acute-on-chronic liver failure (ACLF), but clinically instability can augment the perceived risk of post-transplant mortality at 1 year. We developed a parsimonious score with clinically and readily available parameters to objectively assess 1-year post-LT survival and predict median length of stay after LT. We developed and externally validated a clinical model called the Sundaram ACLF-LT-Mortality score in 521 US patients with ACLF with 2 or ≥3 organ failure(s) and 120 French patients with ACLF grade 3. The c-statistic was 0.72 in the development cohort and 0.80 in the validation cohort. We also provided an estimation of the median length of stay after LT in these patients. Our models can be used in discussions on the risks/benefits of LT in patients listed with severe ACLF. Nevertheless, the score is far from perfect and other factors, such as patient's preference and center-specific factors, need to be considered when using these tools.
引用
- Hernaez R, Karvellas CJ, Liu Y, et al. The novel SALT-M score predicts 1-year post-transplant mortality in patients with severe acute-on-chronic liver failure. J Hepatol. 2023. PMID: 37315809. doi:10.1016/j.jhep.2023.05.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。